First-in-Human Study of a Novel IVL-Based Coronary Crossing Device for Calcified Lesions (Shockwave)

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; Boston Scientific Corporation; Shockwave Medical</li></ul>